Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cancer Vaccines01:30

Cancer Vaccines

340
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
340
Tumor Immunotherapy01:27

Tumor Immunotherapy

480
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
480
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.5K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Programmable mRNA 3'UTR engineering restores MHC-I and overcomes immune evasion in prostate cancer.

Nature biomedical engineering·2026
Same author

Endogenous neoantigen-specific antibodies mediate antitumor responses and determine vaccine efficacy.

Journal for immunotherapy of cancer·2026
Same author

Development of a STEAP1-Targeted Prostate Cancer Specific Antibody Drug Conjugate Platform with Immunostimulatory Properties.

Research square·2026
Same author

CD27 agonism enhances long-lived CD4 T cell vaccine responses critical for antitumor immunity.

Science immunology·2025
Same author

Targeting SREBP-dependent lipogenesis potentiates the anti-tumor activity of docetaxel by increasing membrane permeability and intracellular drug accumulation.

Oncogene·2025
Same author

Effective extracellular payload release and immunomodulatory interactions govern the therapeutic effect of trastuzumab deruxtecan (T-DXd).

Nature communications·2025

Related Experiment Video

Updated: Jun 6, 2025

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

13.0K

Vaccination Against Androgen Receptor Splice Variants to Immunologically Target Prostate Cancer.

Robert D Marek1, Selena Halabi2, Mu-En Wang1,3

  • 1Department of Pathology, Duke University, Durham, NC 27710, USA.

Vaccines
|November 26, 2024
PubMed
Summary

A novel vaccine targeting the androgen receptor variant 7 (AR-V7) shows promise in combating prostate cancer by overcoming immune suppression and enhancing treatment efficacy, even with existing therapies.

Keywords:
androgen receptorcastration resistanceimmune checkpoint inhibitionimmune suppressionprostate cancervaccines

More Related Videos

Virus Delivery of CRISPR Guides to the Murine Prostate for Gene Alteration
06:21

Virus Delivery of CRISPR Guides to the Murine Prostate for Gene Alteration

Published on: April 27, 2018

8.7K
Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients
12:13

Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients

Published on: November 19, 2019

6.8K

Related Experiment Videos

Last Updated: Jun 6, 2025

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

13.0K
Virus Delivery of CRISPR Guides to the Murine Prostate for Gene Alteration
06:21

Virus Delivery of CRISPR Guides to the Murine Prostate for Gene Alteration

Published on: April 27, 2018

8.7K
Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients
12:13

Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients

Published on: November 19, 2019

6.8K

Area of Science:

  • Oncology
  • Immunology
  • Molecular Biology

Background:

  • Androgen receptor (AR) signaling drives prostate cancer progression, but therapies often fail due to AR splice variants like AR-V7.
  • Prostate cancer exhibits significant immunosuppression, limiting the effectiveness of current treatments like immune checkpoint inhibitors.
  • Existing therapies targeting AR axis and PSA-based vaccines have not become standard care for advanced prostate cancer.

Purpose of the Study:

  • To develop and evaluate a vaccine targeting the AR-V7 splice variant.
  • To investigate the role of AR-V7 in prostate cancer-mediated immunosuppression.
  • To assess the therapeutic potential of an AR-V7 vaccine in combination with other treatments.

Main Methods:

  • Development of a vaccine targeting AR-V7.
  • Testing the vaccine's ability to induce AR-V7-specific immunity and anti-tumor responses in preclinical models.
  • Evaluating the combination of AR-V7 vaccination with enzalutamide (an AR antagonist) and anti-PD-1 immune checkpoint inhibition.

Main Results:

  • The AR-V7 vaccine elicited specific immunity and anti-tumor responses in AR-V7+ cancer models.
  • AR-V7 expression was found to promote an immune-suppressive phenotype.
  • Combination therapy of AR-V7 vaccine with enzalutamide suppressed aggressive tumors and improved survival.
  • Vaccination combined with anti-PD-1 therapy led to complete tumor elimination in most cases.

Conclusions:

  • AR signaling plays a crucial role in prostate cancer immune suppression.
  • AR-V7-specific vaccines represent a potential therapeutic strategy for prostate cancer.
  • These vaccines offer significant anti-tumor responses, even when used with androgen signaling inhibitors.